Aspirin use for primary prophylaxis: Adverse outcomes in non-variceal upper gastrointestinal bleeding

Table 2 Association between aspirin use and presentation/management n (%)

Group	No anti-thrombotics n = 263	Aspirin n = 94	P value
Melena	109 (41.4)	51 (54.3)	0.03
Hematemesis	76 (28.9)	17 (18.1)	0.04
Hematemesis + Melena	46 (17.5)	16 (17.05)	0.92
Hematochezia	8 (3.0)	2 (2.1)	0.48
Syncope	33 (12.5)	20 (21.3)	0.04
Hgb, g/L, mean (SD)	9.2 (2.8)	9.1 (2.4)	0.80
Hct, (%), mean (SD)	27.4 (8.2)	27.0 (7.1)	0.70
INR, mean (SD)	1.2 (0.7)	1.0 (0.2)	0.003
Gastric ulcers	40 (15.2)	27 (28.7)	0.004
Duodenal ulcers	65 (24.7)	31 (33.0)	0.12
Erosive esophagitis	31 (11.8)	10 (10.6)	0.76
Erosive gastritis	34 (12.9)	38 (40.4)	< 0.0001
Erosive duodenitis	14 (5.3)	15 (16.0)	0.001
Mallory Weiss	18 (6.8)	4 (4.3)	0.37
Hiatal Hernia	24 (9.1)	11 (11.7)	0.47
AVM	11 (4.2)	3 (3.2)	0.47
Cancer	6 (2.3)	0 (0.0)	0.16
Transfusion-unit	4.7 (5.5)	4.0 (3.8)	0.25
Mean (SD)
Transfusion %	161 (61.2)	66 (70.2)	0.12
Thermal coagulation	25 (9.5)	14 (14.9)	0.15
Hemostatic clips	2 (0.8)	0 (0.0)	0.54
Argon-plasma coagulation	4 (1.5)	2 (2.1)	0.50
Angiography-embolization	1 (0.4)	0 (0.0)	0.74
Surgery	21 (8.0)	5 (5.3)	0.39

P < 0.05 is considered significant. NVUGIB: Non-variceal upper gastrointestinal bleeding; Aspirin: Aspirin only; No anti-thrombotics: Including clopidogrel, coumadin, heparin, ticlopedine and dypiradamole; SD: Standard deviation; Hgb: Hemoglobin; Hct: Hematocrit; INR: International normalized ratio; AVM: Arteriovenous malformation; Surgery as any type of surgical procedure performed to control gastrointestinal bleeding.